BRIEF—Ascentage Pharma and MD Anderson Cancer Center in new collaboration

China-based Ascentage Pharma has entered into a five-year collaboration with the Anderson Cancer Center at the University of Texas to advance the development of five potential new cancer therapies.

The project will leverage Ascentage's proprietary Protein-Protein Interaction drug discovery technology, and the expertise of MD Anderson's leukemia team.

Candidates including an apoptosis-targeting compound and a tyrosine kinase inhibitor will be explored as single-agent therapies, and in combination with approved drugs, against hematologic cancers.